Reply to thread

I agree with you.  The high salaries and compensation packages given by jnj in this recession need to be adjusted according to the real value of what a "detail person" actually produces for the company.  "Detail people" have  always been overpaid.  Every "detail person" should appreciate that they made so much money for decades in this industry.  That is why every pharma/biotech company is now only hiring contract sales reps, college grads, or consultants without benefits.